Tenax Therapeutics Reports Second Quarter 2020 Results and Provides Business Update
(WorldNews Finland)

Contacts Investor Contact: Westwicke, an ICR Company Stephanie Carrington, 646-277-1282 stephanie.carrington@westwicke.com Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products for the critical care market, today reported financial results for the second quarter 2020 and provided a business update. `The recently completed Phase 2 trial of patients with pulmonary hypertension and heart failure with preserved ejection fraction (PH-HFpEF) has garnered significant attention from the medical community. Specifically members of our Scientific Advisory Board are very encouraged by the statistically significant...